3rd Department of Internal Medicine Faculty of Medicine Comenius University in Bratislava
Bratislava, 83101, Slovakia
NCT Number: NCT05325398
Molecular hydrogen H2 acts as antioxidant which selectively reduces cytotoxic harmful reactive oxygen species ROS and concomitantly acts as biological messenger, which mediates several signaling pathways that play cytoprotective role in many human diseases. Due to their small size and high permeability, H2 is easily transportable into subcellular structures as mitochondria.
Looking for future studies?
Notify Me33 year–69 year
All sexes
Interventional
Not applicable
Bratislava, 83101, Slovakia
Non-alcoholic fatty liver disease, NAFLD, is the most common cause of liver disease. According to the forecasts, the non-alcoholic steatohepatitis will be the most common cause of liver transplantation and hepatic mortality in 2030. NAFLD is also a significant risk factor for the development of hepatocellular carcinoma, even in the non-cirrhotic stage of liver disease. The prevention of the progression of NAFLD to NASH (nonalcoholic steatohepatitis) is therefore a key factor in preventing this unfavorable prognosis.
Obesity and its associated comorbidities are among the most widespread and challenging conditions in the confrontation of the medical profession in the 21st century. The main metabolic consequence of obesity is insulin resistance, which is strongly associated with the storage of triacylglycerols in the liver. Hepatic steatosis may be associated with steatohepatitis, a condition that can lead to liver cirrhosis and, in the final stage, liver transplantation.
According to various sources, the incidence of NAFLD in the population is 20-30%, in obese up to 60%, which makes it the most common liver disease. In the USA, it is even 3 times more common than type 2 diabetes mellitus and 5-10 times more common than chronic hepatitis C. The incidence of non-alcoholic steatohepatitis NASH is 2-3% and is now thought to be the cause of up to 80% cryptogenic liver cirrhosis. The risk of developing cirrhosis in patients with simple hepatic steatosis is 1-2% over 8 years.
Insulin resistance, which is defined as an elevated HOMA (homeostasis model assessment) index above 1,4, is found in 70% of patients with NAFLD and plays a major role in the accumulation of triacylglycerols TAG (triacylglyceride) in the liver. Through the rise of hormone-sensitive lipase, hyperinsulinemia leads to the hydrolysis of free fatty acids FFA from visceral adipocytes to the portal vein, through which they enter directly into the liver, where they are esterified to TAG. Reducing the production of apolipoprotein B-100, which is an important part of their secretion from the liver into the circulation in the form of VLDL-lipoproteins, is also a potentiating factor in TAG deposition in the liver. Free oxygen radicals ROS (reactive oxygen species), which are formed due to the oxidative stress, are formed directly in the hepatocyte. However, their formation in visceral adipocytes has also been shown to be involved in liver damage. The main site of ROS are mitochondria. In NAFLD, known mitochondrial dysfunction leads to pathological oxidation of FFA (free fatty acid) in peroxisomes and microsomes, making them another source of ROS. ROS, through damage of the mitochondrial membrane by lipoperoxidation and induction of Fas-ligand expression on the hepatocyte, leads to cell apoptosis.
By activating stellate cells, a larger amount of extracellular matrix is formed - Mallory's hyaline, which is associated with the formation of balloon degeneration of hepatocytes, that is a typical histological feature of NASH.
From the cytokines, TNF-alpha is mainly used. It is formed by hepatocytes due to the increased supply of FFA. The diagnostic process is often random. One of the options for non-invasive measurement of liver fibrosis is transient elastography FibroScan, which is used for direct measurement of liver elasticity or use of noninvasive fibrosis indexes (NFS, Fib-4, APRI etc) as nondirect tools. Initial studies have confirmed that H2 penetrates cell membranes and protects mitochondria and cell nuclei from acute oxidative stress. Several studies have reported the effect of H2 on mitochondrial function. With H2, the investigators protect the potential of the mitochondrial membrane, increase ATP production and reduce organelle swelling. There are at least four possible mechanisms for H2 through which gene expression can be altered through mitochondrial bioenergetics, of which ghrelin is probably the most important. Ghrelin is the hormone responsible for appetite.
It reaches its maximum level during hunger. Obestatin has the opposite effect, which in turn suppresses the feeling of hunger. The role of ghrelin as an energy modulator in H2 intervention may be promoted by interaction with expressed glucose transporters, which increase glucose consumption and modulate oxidative phosphorylation in mitochondria. Exercise led to a significant change in ghrelin levels but had no effect on plasma levels of obestatin.
Molecular hydrogen has been shown to relieve oxidative stress, have an anti-inflammatory effect and improve lipid, glucose and energy production in patients as well as in animal models of hepatic steatosis and atherosclerosis. The basic molecular mechanisms remain largely unknown.
Molecular hydrogen is an effective antioxidant that reduces cytotoxic reactive oxygen radicals, especially the hydroxyl radical. In several previous experiments, the use of hydrogen-enriched water, HRW, has been shown to have antioxidant effects. The effects of hydrogen on the prevention of hepatocarcinogenesis in STAM mice were also investigated. The number of tumors was significantly lower in the HRW groups and the tumors were smaller than in the other groups. The results clearly demonstrated that HRW can be an effective treatment for apoptosis, inflammation and hepatocarcinogenesis in NAFLD.
The aim of the study is to verify effectiveness and safety of molecular hydrogen on a group of patients with NAFLD.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The cohort will consist of 17 patients with NAFLD. Name of the product that will be the source of molecular hydrogen: HRW drink, HRW Natural Health Products Inc., Made in Vancouver, Canada. It is a nutritional supplement that is a source of molecular hydrogen.
All study participants will drink one tablet dissolved in 0.33 l of tap water every 8 hours.
They did this for 8 weeks. Blood analysis at study entry and after 8 weeks (end of study).
13 probands in the control group who will receive placebo. All study participants will drink one placebo tablet dissolved in 0.33 l of tap water every 8 hours.
They did this for 8 weeks. Blood analysis at study entry and after 8 weeks (end of study)
Time frame: 8 weeks
The following parameters will be measured for each proband before (time 0) and after the study (time 8 weeks):
a) weight and height will be combined to report BMI in kg/m^2, waist circumference in cm.
Time frame: 8 weeks
ALT (alaninaminotransferase) ukat/L
Time frame: 8 weeks
AST (aspartataminotransferase) ukat/L
Time frame: 8 weeks
ALP (alkaline phosphatase) ukat/L
Time frame: 8 weeks
GMT (gamaglutamyltransferase) ukat/L
Time frame: 8 weeks
Albumin (g/L)
Time frame: 8 weeks
Cholinesterase (ukat/L)
Time frame: 8 weeks
Bilirubin total (umol/L)
Time frame: 8 weeks
Glucose (mmol/L)
Time frame: 8 weeks
Cholesterol (mmol/L)
Time frame: 8 weeks
Triacylglycerol (mmol/L)
Time frame: 8 weeks
Insulin (mIU/L)
Time frame: 8 weeks
HOMA index (calculation)
Time frame: 8 weeks
Leucocytes (x10^9/L)
Time frame: 8 weeks
Hemoglobin (g/L)
Time frame: 8 weeks
Platelets (x10^9/L)
Time frame: 8 weeks
TBARS (μmol/L)
Time frame: 8 weeks
MDA (malondialdehyde) (μmol/L)
Time frame: 8 weeks
LDH (lactatdehydrogenase) (mU/mL)
Time frame: 8 weeks
MMP-2 (matrix metalloproteinase2) (% of change)
Time frame: 8 weeks
MMP-9 (matrix-metalloproteinase 9) (% of change)
Time frame: 8 weeks
8-OHdG (8-hydroxy-2-deoxyguanosine) (ng/mL)
Time frame: 8 weeks
SOD (superoxiddismutase) (ng/mL)
Time frame: 8 weeks
NFkB (nuclear factor kappa B) (% of change)
Time frame: 8 weeks
TNF alfa (tumor necrosis factor alpha) (% of change)
Time frame: 8 weeks
HSP 60 (heat shock protein 60) (% of change)
Time frame: 8 weeks
HSP 70 (heat shock protein 70) (% of change)
Time frame: 8 weeks
Alpha tocopherol (μmol/L)
Time frame: 8 weeks
Gama tocopherol (μmol/L)
Time frame: 8 weeks
Beta carotene (μmol/L)
Time frame: 8 weeks
Coenzyme Q 10 in platelets (pmol/10^9 cells)
Time frame: 8 weeks
Coenzyme Q 10 in plasma (μmol/L)
Time frame: 8 weeks
Coenzyme Q 10 in whole blood (μmol/L)
Time frame: 2 hours
Entry examination will include:
SPG: Status presens generalis (consciousness, body habitus, skin, nutrition), SPL: status presens localis (head, neck, chest, abdomen, limbs)- described generally as number of participants with changes in healt status
Time frame: 2 hours
Urinary sediment normal : leucocyte 1-2 , erythrocyte: 0-1, cultivation: negative or bacterial agens more than 10^5 - described generally as number of participants with changes in urinary sedinent status (normal/abnormal)
Time frame: 2 hours
USG: Ultrasonographic examination: fatty liver: enlargement of the liver more than 130 mm in anteroposterior position, enlarged echogenity of the liver, curved anterior liver lobe. 1 of these parameter is sufficient for diagnosis of fatty liver - described generally as number of participants with changes in urinary sedinent status (normal/abnormal)
Time frame: 1 hours
Filling of the following Questionnaire: Life style risk factors questionnaire Part A/ NAFLD score more as 7 points means risk of nonalcoholic fatty liver disease (NAFLD) Minimum: 0 points Maximum: 14 points Part. B/ ALD score (AUDIT C questionnaire) more than 5 points = risk of alcoholic liver disease (ALD) Minimum: 0 points Maximum: 12 points 5 points and more = risk of ALD , risk of worse outcome
Time frame: 30 minutes
Filling of the following Questionnaire: AUDIT questionnaire of alcohol intake Minimum: 0 points Maximum: 40 points 8 points and more= risky alcohol drinking , risk of ALD , risk of worse outcome
Time frame: 10 minutes
Filling of the following Questionnaire: Fast Depression screening by Patient Health Questionnaire (2 questions) Minimum: 0 points Maximum: 6 points 3 points and more: risk for depression, risk of worse outcome
Time frame: 10 minutes
Filling of the following Questionnaire: Generalized Anxiety Disorder (2 questions) Minimum: 0 points Maximum: 4 points 3 points and more: risk for generalized anxiety disorder, risk of worse outcome
Comenius University
Other
Effect of Molecular Hydrogen in Patients With Non Alcoholic Faty Liver Disease
Acronym: EMoHyNAFLD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05268042
Body Weight, Digestive System Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT04785937
Digestive System Diseases, Fatty Liver
Reggio Emilia, RE, Italy
View Trial DetailsNCT00230087
Diabetes Mellitus, Digestive System Diseases
Seattle, Washington, United States
View Trial DetailsNCT00230113
Digestive System Diseases, Fatty Liver
Seattle, Washington, United States
View Trial Details